author_facet Tan, Esther
Lindenberg, Liza
Korde, Neha
Berg, Alexandra
Mena, Esther
Turkbey, Baris
Aras, Omer
Steinberg, Seth M.
Weiss, Brendan
Minter, Alex
Yancey, Mary Ann
Mulquin, Marcia
Choyke, Peter
Kurdziel, Karen
Landgren, Ola
Tan, Esther
Lindenberg, Liza
Korde, Neha
Berg, Alexandra
Mena, Esther
Turkbey, Baris
Aras, Omer
Steinberg, Seth M.
Weiss, Brendan
Minter, Alex
Yancey, Mary Ann
Mulquin, Marcia
Choyke, Peter
Kurdziel, Karen
Landgren, Ola
author Tan, Esther
Lindenberg, Liza
Korde, Neha
Berg, Alexandra
Mena, Esther
Turkbey, Baris
Aras, Omer
Steinberg, Seth M.
Weiss, Brendan
Minter, Alex
Yancey, Mary Ann
Mulquin, Marcia
Choyke, Peter
Kurdziel, Karen
Landgren, Ola
spellingShingle Tan, Esther
Lindenberg, Liza
Korde, Neha
Berg, Alexandra
Mena, Esther
Turkbey, Baris
Aras, Omer
Steinberg, Seth M.
Weiss, Brendan
Minter, Alex
Yancey, Mary Ann
Mulquin, Marcia
Choyke, Peter
Kurdziel, Karen
Landgren, Ola
Blood
Novel Molecular Imaging Detects Evidence of Altered Bone Marrow Biology in Myeloma Precursor Disease (MGUS and smoldering myeloma): A Prospective Clinical Study
Cell Biology
Hematology
Immunology
Biochemistry
author_sort tan, esther
spelling Tan, Esther Lindenberg, Liza Korde, Neha Berg, Alexandra Mena, Esther Turkbey, Baris Aras, Omer Steinberg, Seth M. Weiss, Brendan Minter, Alex Yancey, Mary Ann Mulquin, Marcia Choyke, Peter Kurdziel, Karen Landgren, Ola 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood.v118.21.2888.2888 <jats:title>Abstract</jats:title> <jats:p>Abstract 2888</jats:p> <jats:p>Despite its poor sensitivity to detect bone lesions, its inability to define focal disease in the bone marrow, and its incapacity to identify extramedullary disease; skeletal survey remains the gold standard in multiple myeloma (MM). We conducted a prospective clinical study to evaluate novel molecular imaging in MM and its precursors (monoclonal gammopathy of undetermined significance, MGUS; smoldering myeloma, SMM).</jats:p> <jats:p>We included 10 MGUS, 10 SMM, and 10 MM (2/8; untreated/treated) patients. To define evidence of osteolytic lesions and extramedullary disease, all patients were assessed by skeletal survey, fluorine-18 fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT), 18F-sodium fluoride (18F-NaF) PET/CT. To assess bone marrow vascularity we conducted dynamic contrast enhanced-magnetic resonance imaging (DCE-MRI). Using DCE-MRI, we compared exchange rate constants (contrast agent transit from the extravascular compartment to the intravascular compartment, kep ; movement of contrast agent from plasma to extravascular extracellular space, ktrans) with bone marrow biopsies immunostained with CD34 as measures of microvessel density (MVD).</jats:p> <jats:p>All but one MGUS patients were negative by 18F-FDG. One had indeterminate uptake in possible early myelomatous lesions but was negative on 18F-NaF. Two MGUS patients had unexplained focal uptake in bone (one in the left orbital sphenoid and another in the left temporal bone) without CT abnormalities. Two SMM patients had abnormalities by PET/CT. One SMM patient had subtle increased 18F-NaF PET uptake in T12 which corresponded to CT, MRI and DCE-MRI abnormalities in this region; 18F-FDG PET and skeletal survey were negative. Another SMM patient had increased 18F-FDG PET uptake in the left clavicle with negative 18F-NaF that was biopsy proven to be consistent with disease. In 8 MM patients, both 18F-FDG and 18F-NaF PET/CT showed mild to moderate positive PET uptake corresponding with CT abnormalities; the remaining 2 MM patients had CT abnormalities, which were 18F-NaF positive, corresponding with skeletal survey, while 18F-FDG PET was negative. Immunohistochemistry and kep were correlated (r=0.64 and p=0.0003), and DCE-MRI showed higher kep levels in MM versus MGUS patients (mean kep 9.4 vs. 5.0; p&lt;0.05); suggesting that increased MVD may be associated with transformation from early precursor disease to frank malignancy. In 2 MGUS patients and 1 SMM patient, DCE-MRI showed focal disease in the bone marrow.</jats:p> <jats:p>Novel molecular imaging techniques detected evidence of altered bone marrow biology in myeloma precursor disease, which was not found on skeletal survey. Our results emphasize the broad biological and clinical heterogeneity in myeloma precursor disease, and the need for molecularly defined phenotypes. This study provides new avenues for future investigations designed to (1) initiate/monitor early treatment in high-risk myeloma precursor disease and (2) to monitor minimal residual disease and/or to detect early relapse. Detailed imaging, clinical, and molecular data will be presented at the meeting.</jats:p> <jats:sec> <jats:title>Disclosures:</jats:title> <jats:p>No relevant conflicts of interest to declare.</jats:p> </jats:sec> Novel Molecular Imaging Detects Evidence of Altered Bone Marrow Biology in Myeloma Precursor Disease (MGUS and smoldering myeloma): A Prospective Clinical Study Blood
doi_str_mv 10.1182/blood.v118.21.2888.2888
facet_avail Online
Free
finc_class_facet Biologie
Medizin
Chemie und Pharmazie
format ElectronicArticle
fullrecord blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC52MTE4LjIxLjI4ODguMjg4OA
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC52MTE4LjIxLjI4ODguMjg4OA
institution DE-Zi4
DE-Gla1
DE-15
DE-Pl11
DE-Rs1
DE-14
DE-105
DE-Ch1
DE-L229
DE-D275
DE-Bn3
DE-Brt1
DE-Zwi2
DE-D161
imprint American Society of Hematology, 2011
imprint_str_mv American Society of Hematology, 2011
issn 0006-4971
1528-0020
issn_str_mv 0006-4971
1528-0020
language English
mega_collection American Society of Hematology (CrossRef)
match_str tan2011novelmolecularimagingdetectsevidenceofalteredbonemarrowbiologyinmyelomaprecursordiseasemgusandsmolderingmyelomaaprospectiveclinicalstudy
publishDateSort 2011
publisher American Society of Hematology
recordtype ai
record_format ai
series Blood
source_id 49
title Novel Molecular Imaging Detects Evidence of Altered Bone Marrow Biology in Myeloma Precursor Disease (MGUS and smoldering myeloma): A Prospective Clinical Study
title_unstemmed Novel Molecular Imaging Detects Evidence of Altered Bone Marrow Biology in Myeloma Precursor Disease (MGUS and smoldering myeloma): A Prospective Clinical Study
title_full Novel Molecular Imaging Detects Evidence of Altered Bone Marrow Biology in Myeloma Precursor Disease (MGUS and smoldering myeloma): A Prospective Clinical Study
title_fullStr Novel Molecular Imaging Detects Evidence of Altered Bone Marrow Biology in Myeloma Precursor Disease (MGUS and smoldering myeloma): A Prospective Clinical Study
title_full_unstemmed Novel Molecular Imaging Detects Evidence of Altered Bone Marrow Biology in Myeloma Precursor Disease (MGUS and smoldering myeloma): A Prospective Clinical Study
title_short Novel Molecular Imaging Detects Evidence of Altered Bone Marrow Biology in Myeloma Precursor Disease (MGUS and smoldering myeloma): A Prospective Clinical Study
title_sort novel molecular imaging detects evidence of altered bone marrow biology in myeloma precursor disease (mgus and smoldering myeloma): a prospective clinical study
topic Cell Biology
Hematology
Immunology
Biochemistry
url http://dx.doi.org/10.1182/blood.v118.21.2888.2888
publishDate 2011
physical 2888-2888
description <jats:title>Abstract</jats:title> <jats:p>Abstract 2888</jats:p> <jats:p>Despite its poor sensitivity to detect bone lesions, its inability to define focal disease in the bone marrow, and its incapacity to identify extramedullary disease; skeletal survey remains the gold standard in multiple myeloma (MM). We conducted a prospective clinical study to evaluate novel molecular imaging in MM and its precursors (monoclonal gammopathy of undetermined significance, MGUS; smoldering myeloma, SMM).</jats:p> <jats:p>We included 10 MGUS, 10 SMM, and 10 MM (2/8; untreated/treated) patients. To define evidence of osteolytic lesions and extramedullary disease, all patients were assessed by skeletal survey, fluorine-18 fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT), 18F-sodium fluoride (18F-NaF) PET/CT. To assess bone marrow vascularity we conducted dynamic contrast enhanced-magnetic resonance imaging (DCE-MRI). Using DCE-MRI, we compared exchange rate constants (contrast agent transit from the extravascular compartment to the intravascular compartment, kep ; movement of contrast agent from plasma to extravascular extracellular space, ktrans) with bone marrow biopsies immunostained with CD34 as measures of microvessel density (MVD).</jats:p> <jats:p>All but one MGUS patients were negative by 18F-FDG. One had indeterminate uptake in possible early myelomatous lesions but was negative on 18F-NaF. Two MGUS patients had unexplained focal uptake in bone (one in the left orbital sphenoid and another in the left temporal bone) without CT abnormalities. Two SMM patients had abnormalities by PET/CT. One SMM patient had subtle increased 18F-NaF PET uptake in T12 which corresponded to CT, MRI and DCE-MRI abnormalities in this region; 18F-FDG PET and skeletal survey were negative. Another SMM patient had increased 18F-FDG PET uptake in the left clavicle with negative 18F-NaF that was biopsy proven to be consistent with disease. In 8 MM patients, both 18F-FDG and 18F-NaF PET/CT showed mild to moderate positive PET uptake corresponding with CT abnormalities; the remaining 2 MM patients had CT abnormalities, which were 18F-NaF positive, corresponding with skeletal survey, while 18F-FDG PET was negative. Immunohistochemistry and kep were correlated (r=0.64 and p=0.0003), and DCE-MRI showed higher kep levels in MM versus MGUS patients (mean kep 9.4 vs. 5.0; p&lt;0.05); suggesting that increased MVD may be associated with transformation from early precursor disease to frank malignancy. In 2 MGUS patients and 1 SMM patient, DCE-MRI showed focal disease in the bone marrow.</jats:p> <jats:p>Novel molecular imaging techniques detected evidence of altered bone marrow biology in myeloma precursor disease, which was not found on skeletal survey. Our results emphasize the broad biological and clinical heterogeneity in myeloma precursor disease, and the need for molecularly defined phenotypes. This study provides new avenues for future investigations designed to (1) initiate/monitor early treatment in high-risk myeloma precursor disease and (2) to monitor minimal residual disease and/or to detect early relapse. Detailed imaging, clinical, and molecular data will be presented at the meeting.</jats:p> <jats:sec> <jats:title>Disclosures:</jats:title> <jats:p>No relevant conflicts of interest to declare.</jats:p> </jats:sec>
container_issue 21
container_start_page 2888
container_title Blood
container_volume 118
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
_version_ 1792324450160476163
geogr_code not assigned
last_indexed 2024-03-01T11:49:46.637Z
geogr_code_person not assigned
openURL url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Novel+Molecular+Imaging+Detects+Evidence+of+Altered+Bone+Marrow+Biology+in+Myeloma+Precursor+Disease+%28MGUS+and+smoldering+myeloma%29%3A+A+Prospective+Clinical+Study&rft.date=2011-11-18&genre=article&issn=1528-0020&volume=118&issue=21&spage=2888&epage=2888&pages=2888-2888&jtitle=Blood&atitle=Novel+Molecular+Imaging+Detects+Evidence+of+Altered+Bone+Marrow+Biology+in+Myeloma+Precursor+Disease+%28MGUS+and+smoldering+myeloma%29%3A+A+Prospective+Clinical+Study&aulast=Landgren&aufirst=Ola&rft_id=info%3Adoi%2F10.1182%2Fblood.v118.21.2888.2888&rft.language%5B0%5D=eng
SOLR
_version_ 1792324450160476163
author Tan, Esther, Lindenberg, Liza, Korde, Neha, Berg, Alexandra, Mena, Esther, Turkbey, Baris, Aras, Omer, Steinberg, Seth M., Weiss, Brendan, Minter, Alex, Yancey, Mary Ann, Mulquin, Marcia, Choyke, Peter, Kurdziel, Karen, Landgren, Ola
author_facet Tan, Esther, Lindenberg, Liza, Korde, Neha, Berg, Alexandra, Mena, Esther, Turkbey, Baris, Aras, Omer, Steinberg, Seth M., Weiss, Brendan, Minter, Alex, Yancey, Mary Ann, Mulquin, Marcia, Choyke, Peter, Kurdziel, Karen, Landgren, Ola, Tan, Esther, Lindenberg, Liza, Korde, Neha, Berg, Alexandra, Mena, Esther, Turkbey, Baris, Aras, Omer, Steinberg, Seth M., Weiss, Brendan, Minter, Alex, Yancey, Mary Ann, Mulquin, Marcia, Choyke, Peter, Kurdziel, Karen, Landgren, Ola
author_sort tan, esther
container_issue 21
container_start_page 2888
container_title Blood
container_volume 118
description <jats:title>Abstract</jats:title> <jats:p>Abstract 2888</jats:p> <jats:p>Despite its poor sensitivity to detect bone lesions, its inability to define focal disease in the bone marrow, and its incapacity to identify extramedullary disease; skeletal survey remains the gold standard in multiple myeloma (MM). We conducted a prospective clinical study to evaluate novel molecular imaging in MM and its precursors (monoclonal gammopathy of undetermined significance, MGUS; smoldering myeloma, SMM).</jats:p> <jats:p>We included 10 MGUS, 10 SMM, and 10 MM (2/8; untreated/treated) patients. To define evidence of osteolytic lesions and extramedullary disease, all patients were assessed by skeletal survey, fluorine-18 fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT), 18F-sodium fluoride (18F-NaF) PET/CT. To assess bone marrow vascularity we conducted dynamic contrast enhanced-magnetic resonance imaging (DCE-MRI). Using DCE-MRI, we compared exchange rate constants (contrast agent transit from the extravascular compartment to the intravascular compartment, kep ; movement of contrast agent from plasma to extravascular extracellular space, ktrans) with bone marrow biopsies immunostained with CD34 as measures of microvessel density (MVD).</jats:p> <jats:p>All but one MGUS patients were negative by 18F-FDG. One had indeterminate uptake in possible early myelomatous lesions but was negative on 18F-NaF. Two MGUS patients had unexplained focal uptake in bone (one in the left orbital sphenoid and another in the left temporal bone) without CT abnormalities. Two SMM patients had abnormalities by PET/CT. One SMM patient had subtle increased 18F-NaF PET uptake in T12 which corresponded to CT, MRI and DCE-MRI abnormalities in this region; 18F-FDG PET and skeletal survey were negative. Another SMM patient had increased 18F-FDG PET uptake in the left clavicle with negative 18F-NaF that was biopsy proven to be consistent with disease. In 8 MM patients, both 18F-FDG and 18F-NaF PET/CT showed mild to moderate positive PET uptake corresponding with CT abnormalities; the remaining 2 MM patients had CT abnormalities, which were 18F-NaF positive, corresponding with skeletal survey, while 18F-FDG PET was negative. Immunohistochemistry and kep were correlated (r=0.64 and p=0.0003), and DCE-MRI showed higher kep levels in MM versus MGUS patients (mean kep 9.4 vs. 5.0; p&lt;0.05); suggesting that increased MVD may be associated with transformation from early precursor disease to frank malignancy. In 2 MGUS patients and 1 SMM patient, DCE-MRI showed focal disease in the bone marrow.</jats:p> <jats:p>Novel molecular imaging techniques detected evidence of altered bone marrow biology in myeloma precursor disease, which was not found on skeletal survey. Our results emphasize the broad biological and clinical heterogeneity in myeloma precursor disease, and the need for molecularly defined phenotypes. This study provides new avenues for future investigations designed to (1) initiate/monitor early treatment in high-risk myeloma precursor disease and (2) to monitor minimal residual disease and/or to detect early relapse. Detailed imaging, clinical, and molecular data will be presented at the meeting.</jats:p> <jats:sec> <jats:title>Disclosures:</jats:title> <jats:p>No relevant conflicts of interest to declare.</jats:p> </jats:sec>
doi_str_mv 10.1182/blood.v118.21.2888.2888
facet_avail Online, Free
finc_class_facet Biologie, Medizin, Chemie und Pharmazie
format ElectronicArticle
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
geogr_code not assigned
geogr_code_person not assigned
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC52MTE4LjIxLjI4ODguMjg4OA
imprint American Society of Hematology, 2011
imprint_str_mv American Society of Hematology, 2011
institution DE-Zi4, DE-Gla1, DE-15, DE-Pl11, DE-Rs1, DE-14, DE-105, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161
issn 0006-4971, 1528-0020
issn_str_mv 0006-4971, 1528-0020
language English
last_indexed 2024-03-01T11:49:46.637Z
match_str tan2011novelmolecularimagingdetectsevidenceofalteredbonemarrowbiologyinmyelomaprecursordiseasemgusandsmolderingmyelomaaprospectiveclinicalstudy
mega_collection American Society of Hematology (CrossRef)
physical 2888-2888
publishDate 2011
publishDateSort 2011
publisher American Society of Hematology
record_format ai
recordtype ai
series Blood
source_id 49
spelling Tan, Esther Lindenberg, Liza Korde, Neha Berg, Alexandra Mena, Esther Turkbey, Baris Aras, Omer Steinberg, Seth M. Weiss, Brendan Minter, Alex Yancey, Mary Ann Mulquin, Marcia Choyke, Peter Kurdziel, Karen Landgren, Ola 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood.v118.21.2888.2888 <jats:title>Abstract</jats:title> <jats:p>Abstract 2888</jats:p> <jats:p>Despite its poor sensitivity to detect bone lesions, its inability to define focal disease in the bone marrow, and its incapacity to identify extramedullary disease; skeletal survey remains the gold standard in multiple myeloma (MM). We conducted a prospective clinical study to evaluate novel molecular imaging in MM and its precursors (monoclonal gammopathy of undetermined significance, MGUS; smoldering myeloma, SMM).</jats:p> <jats:p>We included 10 MGUS, 10 SMM, and 10 MM (2/8; untreated/treated) patients. To define evidence of osteolytic lesions and extramedullary disease, all patients were assessed by skeletal survey, fluorine-18 fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT), 18F-sodium fluoride (18F-NaF) PET/CT. To assess bone marrow vascularity we conducted dynamic contrast enhanced-magnetic resonance imaging (DCE-MRI). Using DCE-MRI, we compared exchange rate constants (contrast agent transit from the extravascular compartment to the intravascular compartment, kep ; movement of contrast agent from plasma to extravascular extracellular space, ktrans) with bone marrow biopsies immunostained with CD34 as measures of microvessel density (MVD).</jats:p> <jats:p>All but one MGUS patients were negative by 18F-FDG. One had indeterminate uptake in possible early myelomatous lesions but was negative on 18F-NaF. Two MGUS patients had unexplained focal uptake in bone (one in the left orbital sphenoid and another in the left temporal bone) without CT abnormalities. Two SMM patients had abnormalities by PET/CT. One SMM patient had subtle increased 18F-NaF PET uptake in T12 which corresponded to CT, MRI and DCE-MRI abnormalities in this region; 18F-FDG PET and skeletal survey were negative. Another SMM patient had increased 18F-FDG PET uptake in the left clavicle with negative 18F-NaF that was biopsy proven to be consistent with disease. In 8 MM patients, both 18F-FDG and 18F-NaF PET/CT showed mild to moderate positive PET uptake corresponding with CT abnormalities; the remaining 2 MM patients had CT abnormalities, which were 18F-NaF positive, corresponding with skeletal survey, while 18F-FDG PET was negative. Immunohistochemistry and kep were correlated (r=0.64 and p=0.0003), and DCE-MRI showed higher kep levels in MM versus MGUS patients (mean kep 9.4 vs. 5.0; p&lt;0.05); suggesting that increased MVD may be associated with transformation from early precursor disease to frank malignancy. In 2 MGUS patients and 1 SMM patient, DCE-MRI showed focal disease in the bone marrow.</jats:p> <jats:p>Novel molecular imaging techniques detected evidence of altered bone marrow biology in myeloma precursor disease, which was not found on skeletal survey. Our results emphasize the broad biological and clinical heterogeneity in myeloma precursor disease, and the need for molecularly defined phenotypes. This study provides new avenues for future investigations designed to (1) initiate/monitor early treatment in high-risk myeloma precursor disease and (2) to monitor minimal residual disease and/or to detect early relapse. Detailed imaging, clinical, and molecular data will be presented at the meeting.</jats:p> <jats:sec> <jats:title>Disclosures:</jats:title> <jats:p>No relevant conflicts of interest to declare.</jats:p> </jats:sec> Novel Molecular Imaging Detects Evidence of Altered Bone Marrow Biology in Myeloma Precursor Disease (MGUS and smoldering myeloma): A Prospective Clinical Study Blood
spellingShingle Tan, Esther, Lindenberg, Liza, Korde, Neha, Berg, Alexandra, Mena, Esther, Turkbey, Baris, Aras, Omer, Steinberg, Seth M., Weiss, Brendan, Minter, Alex, Yancey, Mary Ann, Mulquin, Marcia, Choyke, Peter, Kurdziel, Karen, Landgren, Ola, Blood, Novel Molecular Imaging Detects Evidence of Altered Bone Marrow Biology in Myeloma Precursor Disease (MGUS and smoldering myeloma): A Prospective Clinical Study, Cell Biology, Hematology, Immunology, Biochemistry
title Novel Molecular Imaging Detects Evidence of Altered Bone Marrow Biology in Myeloma Precursor Disease (MGUS and smoldering myeloma): A Prospective Clinical Study
title_full Novel Molecular Imaging Detects Evidence of Altered Bone Marrow Biology in Myeloma Precursor Disease (MGUS and smoldering myeloma): A Prospective Clinical Study
title_fullStr Novel Molecular Imaging Detects Evidence of Altered Bone Marrow Biology in Myeloma Precursor Disease (MGUS and smoldering myeloma): A Prospective Clinical Study
title_full_unstemmed Novel Molecular Imaging Detects Evidence of Altered Bone Marrow Biology in Myeloma Precursor Disease (MGUS and smoldering myeloma): A Prospective Clinical Study
title_short Novel Molecular Imaging Detects Evidence of Altered Bone Marrow Biology in Myeloma Precursor Disease (MGUS and smoldering myeloma): A Prospective Clinical Study
title_sort novel molecular imaging detects evidence of altered bone marrow biology in myeloma precursor disease (mgus and smoldering myeloma): a prospective clinical study
title_unstemmed Novel Molecular Imaging Detects Evidence of Altered Bone Marrow Biology in Myeloma Precursor Disease (MGUS and smoldering myeloma): A Prospective Clinical Study
topic Cell Biology, Hematology, Immunology, Biochemistry
url http://dx.doi.org/10.1182/blood.v118.21.2888.2888